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Nonenzymatically glycated albumin (Amadori adducts) enhances nitric
oxide synthase activity and gene expression in endothelial cells. Hyper-
glycemia is considered to induce diabetic nephropathy through nonenzy-
matic glycation of proteins. Since hyperfiltration is likely to be the
mechanism initiating the glomerular lesions, we investigated the effects of
Amadori glucose adducts in serum albumin on the production of vasoac-
tive mediators, including nitric oxide (NO) and eicosanoids, by endothelial
cells (EC). Amadori adducts of glycated albumin induced a dose-response
increase in NO synthase activity of murine endothelioma cells, up to
16.4 2.1-fold increase of basal values (P < 0.0001) at concentrations of
35 mg/mI mimiking physiological serum albumin concentration, and 4.6
0.8-fold increase at 17 mg/mI (P < 0.001). The effect was still detectable
with glycated albumin 1.7 mg/mI, which approaches its estimated concen-
tration in diabetic serum (1.6 0.3-fold increase, P < 0.05) The
phenomenon was reproducible in human umbilical vein endothelial cells,
though to a lesser extent, and further studies on murine EC were
employed. The mRNA encoding for inducible NO synthase was overex-
pressed in EC incubated with Amadori adducts of glycated albumin in
comparison to native albumin. Glycated albumin induced increased
mRNA expression and synthesis of TNF-a. The stimulatory effect induced
by glycated albumin on NO synthase activity was almost completely
inhibited by anti TNF alpha antibodies. 3H-thymidine incorporation by EC
was significantly inhibited when cells were grown in presence of glycated
albumin (P < 0.001), and the phenomenon was abolished by the coincu-
bation of the NO competitive inhibitor L-NAME. The early glycosylation
products increased thromboxane production (P < 0.001), while prosta-
glandin E2 synthesis was unaffected. These data indicate that Amadori
products of glycated albumin modulate NO synthase activity and eico-
sanoid balance in EC. These effects may be relevant to the hemodynamic
changes in the early phases of diabetic nephropathy and in the lasting
progression to sclerosis.
The pathogenesis of diabetic nephropathy, one of the most
common cause of chronic renal failure worldwide [1], is incom-
pletely understood.
Hyperglycemia per Se in cultured endothelial and mesangial
cells induces antiproliferative effects [2, 3], increased expression
of specific mRNA encoding for TGF-f3 [3] or type I and IV
collagen and other extracellular matrix components [4, 51. Fur-
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thermore, several potential pathogenetical mechanisms are en-
hanced, including aberration of glomerular polyol/sorbitol path-
ways [6], abnormal synthesis of growth factors [71, and
glycosylation of glomerular structures [8]. It has been recently
suggested that the effects of high glucose on glomerular cells are
mediated by the binding to cell receptors of nonenzymatically
glycated serum proteins [9, 10].
Nonenzymatic glycation of long-lived proteins begins with the
spontaneous and reversible condensation of a reducing sugar with
a free amino group, usually the epsilon-amino group of a lysine
residue [11—19]. The resulting Schiff base may undergo Amadori
rearrangement to form a ketoamine adduct that can condense
with an adjacent ketoamine adduct of amino acid side chain to
form an irreversible cross link product known as an advanced
glycation end product (AGE).
Amadori adducts are the prominent form of circulating gly-
cated proteins in vivo, and their concentration is significantly
increased in diabetes during hyperglycemia [11, 20]. Cohen and
Ziyadeh have recently demonstrated that Amadori adducts in
glycated serum albumin impair the proliferative index and in-
crease the synthesis and gene expression of type IV collagen in
mesangial cells [10]. Moreover, the mesangial expansion observed
in a rodent model of genetic diabetes was significantly attenuated
injecting an antibody selectively reacting with Amadori adduets
[21, 22]. The mechanism by which early glycosylated products of
albumin inhibit cell proliferation and enhance matrix components
synthesis is still unknown, but the above observations suggest an
interaction of Amadori products with specific cell receptors.
Endothelial cells bind glycated albumin that behaves as a bifunc-
tional ligand, having a plasma membrane site that binds with a
lectinic bond glucose on glycated albumin and another site that
recognizes domains in the albumin molecule proteic portion [9].
Glomerular hyperfiltration characterizes the early phases of
diabetes both in humans and in experimental models. However,
the lack of a simple direct correlation between hyperglycemia and
increase in glomerular filtration rate [23] suggests the involvement
of additional mediators [24, 25]. Among the others, particular
interest has recently been focused on early nonenzymatically
glycated Amadori configurated proteins, following the observa-
tion that glomerular hyperfiltration was inducible in normal rats
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by transfusing glycated serum proteins containing Amadori prod-
ucts [261.
One of the most powerful vasodilators involved in the regula-
tion of glomerular hemodyriamics [27] is nitric oxide (NO), mostly
produced by endothelial cells. The levels of NO-2!NO-3, which
are stable products of NO, were found to he elevated in hyperfil-
tering streptozotocin-diabetic rats; nitro-L-arginine, an inhibitor
of the specific enzyme NO synthase, blunted this phenomenon
with a parallel decrease in glomerular filtration rate and renal
blood flow [28]. These data indicate that NO synthase activity
increases in experimental diabetes, and suggest that NO is likely
to be involved in the development of glomerular hyperfiltration.
On the other hand, advanced glycosylation products were found
to quench NO activity, thus impairing its vasodilatory effect and
favoring the final vessel narrowing which characterizes end-stage
diabetic complications [29].
We speculated that glycosylated products could variously mod-
ulate NO synthase activity of endothelial cells and that early
adducts (Amadori configurated) could be responsible for an
up-regulation of the NO synthase gene transcription. Addition-
ally, we considered the possibility that these early glycosylated
products in the albumin molecule play a role in other mechanisms
involved in vascular damage modulating arachidonic acid metab-
olism and proliferative rate of endothelial cells. Since advanced
glycosylated products induce in macrophages an increased gene
expression and synthesis of TNF-a, [30] a growth factor involved
in the regulation of cellular proliferation and matrix component
synthesis [31], and recently demonstrated to be implicated in the
development of diabetic nephropathy [30], we also evaluated the
effect induced by Amadori adducts in glycated albumin on TNF-a
production by endothelial cells.
Methods
Early (Amadori configurated) glycation products of human serum
albumin
Cohen's protocol was strictly followed as previously described
[10]. Human serum albumin (Farma-Biagini, Castelvecchio Pas-
coli, Lucca, Italy) was incubated at 37°C, with a fully sterile
procedure, with very high concentration of glucose (450 mM) for
five days. These conditions induce the greatest production of
Amadori adducts, while a longer incubation time induces the
formation of AGEs [11, 26]. Glycated human serum albumin was
then dialyzed for 24 hours against phosphate buffered-saline
(PBS) to remove unbound glucose, and finally was sterile filtered.
Unincubated human serum albumin (normal serum albumin) was
also dialyzed against PBS as a control for the effects of the dialysis
procedures, and sterile filtered.
Early glycosylation products in human serum albumin were
purified by affinity chromatography on phenylboronate agarose
(PBA) as described by others [10], following the indications that
Amadori adducts bind to PBA, while AGE products do not.
Cells
Murine cells. The murine endothelioma cell line t.End.1 [32]
was maintained in Dulbecco's-modified Eagle medium (DMEM;
Sigma Chemical Co., St. Louis, MO, USA) containing 10% FCS
(Sigma), penicillin, streptomycin, and amphotericine (Sigma).
Experiments were performed at the 98 to 166th passages. The
mouse endothelial cell line t.End.1, derived from a thymic heman-
gioma expressing the polyoma middle T antigen [33], retains the
functional properties of normal endothelial cells. These cells
proliferate at confluence without aspects of overgrowth, take up
acetylated low density lipoproteins and express CD31, VCAM-i,
E-selectin and P-seiectin, respond to IL-lp, TNF-a and specific
endothelial cell growth factors, and produce IL-6 and chemokines
[33, 34].
Human cells. Human umbilical vein cells (HUVEC) were
harvested and cultured according to Jaffe et al [35] in growth
medium, 199 medium supplemented with Earle's salts (Sigma),
containing 20% heat-inactivated FCS (Sigma), penicillin, strepto-
mycin, amphotericin (Sigma), 25 jsg/ml EC growth supplement
and heparin 90 jsg/ml (Sigma). Cells were used at the 4th passage.
Culture conditions
Endothelial cells, both murine and humans, were cultured at
37°C in an environment of 95% air and 5% CO2 and in DMEM
or 199 supplemented media. Cells were then incubated for 12
hours with Amadori adducts of glycated albumin or normal
human serum albumin at graded dilutions ranging from 35 mg/mI,
mimiking the physiological serum albumin concentration, to 0.34
mg/ml. Since aminoguanidine (AMG) preferentially binds Ama-
don adducts forming unreactive substituted products [36], we
used this drug (Sigma) at the concentration of 0.005 M as a
negative control. LPS, a well known inducer of NO synthase
activity and TNF-a production, was used at the concentration of
10 ng/ml as the positive control. Anti-TNF-a antibodies at the
concentrations of 10 pg/mI (IP-400; Genzyme, Cambridge, MA,
USA) were used in inhibition experiments, together with glycated
albumin 35 mg/mI. Cellular culture supernatants were collected
for prostaglandin E2 (PGE2), thromboxane B2 (TXB2) and
TNF-n measurements. The cells were snap frozen and stored at
—70°C until the study of NO synthase activity or RNA extraction.
Measurement of NO synthase (NOS) activity in endothelial cells
Endothelial cells were frozen in I ml of reaction buffer (mM:
Hepes 20, EDTA 0.5, dithiothreitol 1, pH 7.2), sonicated on ice
with three 10-second bursts. In each test tube the following
reagents were added to the 100 d sonicate at the final concen-
trations: 2 m'vi NAPDH, 1.5 mrvi CaC12, ito 100 /SM L-Arg, 2.5 MCi
(= 0.4 MM) L-[2,3,4,5-3H]arginine monohydrochloride (62 Ci!
mmol; Amersham International, Bucks, UK). After a 30 minute
incubation at 37°C, the reaction was stopped by adding 2 ml of 20
mM Hepes-Na pH 6 containing 2 mi EDTA. The whole reaction
mixture was applied to 2-mi columns of Dowex AG5OWX-8 (Na
form; Aldrich, Milano, Italy) and eluted with 4 ml of water. At pH
6 arginine is negatively charged, while citrulline is neutral; the
Dowex resin is a cationic exchanger which binds arginine but not
citrulline in these conditions. The radioactivity corresponding to
[3H]citrulline content in 6 ml eiuate was measured by liquid
scintillation counting. NOS activity was expressed as pmoles of
citrulline generated/minute of incubation/mg endothelial cell pro-
tein. The protein content of endothelial cells was assessed with the
modified micro-Lowry method (kit from Sigma). NO synthase
activity was expressed as fold increase in comparison to the basal
value.
RNA extraction and qualitative RT-PCR amplification of mRNA
for inducible NOS (iNOS) and TNF-a
Total RNA was extracted from endothelial cells cultured in
unconditioned medium or with glycated albumin 35 mg/ml or
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native serum albumin 35 mg/mi, and snap frozen in liquid nitrogen
by using the RNAzol (Cinna-Biotech, Houston, TX, USA)
method following the instructions furnished by the producers.
Briefly, endothelial cells were suspended in RNAzol at the
proportion of iO cells/mi. The suspension was vortexed for 15
seconds and incubated in chloroform at 4°C for 15 minutes. After
centrifugation at 12,000 g at 4°C for 15 minutes the supernatant
was extracted with an equal volume of isopropanolol. After
another incubation at —20°C for 45 minutes and centrifugation at
12,000 g for 15 minutes, the pellet was washed twice in 75%
ethanol and resuspended in double distilled water. The concen-
tration and purity of RNA were determined by the absorbance at
260 and 280 nm.
Reverse transcription of total RNA to cDNA was performed
using the reverse transcription system (Promega Co., Madison,
WI, USA).
Briefly, 2 sg of total RNA were transcribed to cDNAs adding
reverse transcriptase 25 U, oligo T I jsg, 10 mM dNTP mixture 5
jsl, RNAsin 20 U, 25 ms'i MgCI2 JO 1J. The whole mixture was
incubated at 42°C for 30 minutes.
The cDNAs specific for iNOS and TNF-a were amplified by
polymerase chain reaction technique using the Taq polymerase kit
(Perkin-Elmer Cetus, Norwalk, CT, USA) employing the follow-
ing primers specific for iNOS (up: 5'-CgTggAggCTgCCCggCA-
gACTgg-3'; down: 5' -TgCCCggAAggTTTgTACAgCCCA-3')
[37] and commercial primers for murine TNF-a (Clontech Lab-
oratories, Palo Alto, CA, USA). Five microliters of eDNA were
added to the following primers: MgC12, dNTP, Taq polymerase 1.2
U, and amplification buffer. Thirty cycles of amplification were
performed (1 mm at 60°C, 1 mm at 94°C; 2 mm at 60°C and 3 mm
at 72°C). The obtained cDNA was then run on a 1% agarose gel
and bands were visualized after ethidium bromide staining on a
UV transiliuminator. The specificity of the bands was confirmed
by Southern blot using iNOS eDNA [37]. As the housekeeping
control gene, we amplified mouse 13-actin mRNA using commer-
cial primers (Clontech Laboratories).
DNA synthesis
[3H]-thymidine incorporation assay was performed in 96-well
microtiter plates in 200 pi total volume. At the end of the 24-hour
incubation period in various experimental conditions [native
serum albumin, glycated albumin, 0.01 M N & nitro-L-arginine
methyl ester (L-NAME), LPS 10 ng/ml, AMG 0.005 M (Sigma) or
unsupplemented media], cells were pulsed overnight with [3H]-
thymidine (1 jsCi/well, 5 to 7 Ci/mmol; Amersham). Cells were
collected on glass microfiber filters (934-AH; Whatman, Clifton,
NJ, USA) using a cell harvester, and radioactivity was assessed
after placing the filters in liquid scintillation fluid and counting in
a liquid scintillation (3-counter.
PGE2 and TXB2 secretion
PGE2 and TxB2 were determined in the cell culture superna-
tants by using commercial kits (Perseptive Diagnostics, Inc.,
Cambridge, MA, USA). The assays are based on the competition
of variable amounts of PGE2 and TxB2 in samples with a fixed
amount of alkaline phosphatase-labeled PGE2 and TxB2 for a
limited number of binding sites on a rabbit anti-PGE2 and TXB2
antibodies. The higher the concentration of the compound in the
sample, the less labeled compound is bound to the specific
antibodies. The unbound material is removed by washing. A
colored product, after the addition of the specific substrate for
alkaline phosphatase, para-nitrophenyl phosphate, is formed in-
versely proportionally to the amount of unlabeled PGE2 or TXB2
bound. The absorbance was measured at 405 nm and correlated
with concentration by means a standard curve. The levels of
eicosanoids were corrected for the protein cellular content mea-
sured by modified micro-Lowry method (Kit from Sigma).
TNF measurement
TNF-a was measured in supernatants of endothelial cells
incubated for six hours with supplemented and unsupplemented
medium by a commercial competitive immunoassay (T Cell
Diagnostic Inc., Cambridge, MA, USA) according to the instruc-
tions of the manufacturer. The levels of TNF-a were corrected for
the protein cellular content and expressed as the fold increase in
comparison to the basal value.
Statistical analysis
Values reported in the results represent mean± SD of five
experiments each performed in triplicate. ANOVA analysis of
variance was used to compare results obtained in different exper-
imental conditions.
Results
NO synthase activity
Normal human serum albumin at concentrations of 35 mg/mI
and 17 mg/mi did not modify the basal NO synthase (NOS)
activity of endothelial cells (1.12 0.04; 1.24 0.03-fold increase
of the basal values, P not significant). Amadori adducts of glycated
human serum albumin at similar concentrations induced a 16.4
2.1 and a 4.6.±0.8 fold-increase, respectively, of the basal values
(P < 0.0001, P < 0.001, respectively). These levels were also
significantly higher than those found when cells were grown in
media containing normal serum albumin at similar concentrations
(P < 0.0001, P < 0.001; Fig. 1). The effect was still detectable with
glycated albumin 1.7 mg/mI, which approaches its estimated
concentration in diabetic serum (1.6 0.3-fold increase, P < 0.05;
Fig. 2). The coincubation with aminoguanidine significantly
blunted these values (8.7 1.1 and 2.1 0.7-fold increase; both
P < 0.01). As expected LPS acted as a potent enhancer of NOS
activity inducing a 22.3 3.1-fold increase of basal values (P <
0.0001). Surprisingly, the coincubation of aminoguanidine signif-
icantly reduced the stimuli induced by LPS (11.8 2.2, P <
0.001), probably through a binding to the glycated residues of
lypopolysaccharide. Aminoguanidine by itself did not modify the
basal endothelial cell NOS activity (Fig. 1).
The phenomenon of NOS enhancement by glycated albumin
was reproducible in HUVEC though at a lesser extent (35 mg/mI
of glycated albumin induced a 3.36 0.2-fold increase of basal
values, P < 0.05; Fig. 3).
The coincubation of EC with 10 pg/mI of anti-TNF antibody
almost completely reversed (78%) the stimulatory effect on NO
synthase activity induced by high concentrations (35 mg/mI) of
Amadori adducts of glycated albumin (Fig. 1).
Qualitative expression of NO synthase mRNA
Early glycosylation products of albumin induced a clear expres-
sion of the specific mRNA encoding for the inducible form of
NOS (iNOS), while normal human albumin was ineffective (Fig.
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DNA synthesis
Normal albumin did not show any effect on EC DNA synthesis
(Fig. 5).
Amadori adducts in glycated albumin at the concentration of 35
and 17 mg/mI induced a significant reduction (80 8% and 70
13%, respectively; both P < 0.001 vs. basal levels) of the DNA
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Fig. 1. NOS activity of murine endothelial cells
after incubation with Glycated albumin and
normal albumin. Results are expressed as the
fold of basal values (mean SD of 5
experiments). P values refer to the ANOVA
test. Abbreviations are: Basal, EC cultured in
unsupplemented medium; Aib, native human
serum albumin; Glyc Aib, glycated human
serum albumin; AMG, aminoguanidine 0.05 M;
LPS, lipopolysaccharide 10 p.g/ml; L-NAME, N
e nitro-L-arginine methyl ester 0.01 anti-
TNF-a, antibodies to tumor necrosis factor
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Fig. 2. Dose-response curve of murine endothelial cells NOS activity after
incubation with graded concentrations of glycated albumin. Results are
expressed as the fold of basal values (mean SD of 5 experiments).
Abbreviations are in the legend to Figure 1.
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Fig. 3. Dose-response curve of HUVEC NOS activity after incubation with
graded concentrations of glycated albumin. Results are expressed as the fold
of basal values (mean SD of 5 experiments). Abbreviations are in the
legend to Figure 1.
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Fig. 4. PCR amplification of specific mRNA encoding for inducible NOS in
endothelial cells. The lanes are: 1, native serum albumin 35 mg/mI; 2,
glycated albumin 35 mg/mI; 3, glycated albumin 35 mg/mI + AMG; 4,
normal serum albumin 17 mg/mI; 5, glycated albumin 17 mg/mI; 6, glycated
albumin 17 mg/mI + AMG; 7, LPS 10 jLg/ml; 8, LPS 10 eg/ml + AMG.
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human albumin. The coincubation with aminoguanidine blunted
the phenomena (46 5%).
The coincubation of EC with glycated albumin in presence of
0.01 M L-NAME completely reversed the inhibitory effect induced
by glycated albumin (3 2.5% reduction in proliferative index vs.
80 8% decrease induced by glycated albumin 35 mg/mI).
Eicosanoid synthesis
Two metabolites of arachidonic acid, thromboxane B2 (end-
product of thromboxane A2), which is a powerful vasoconstrictive
agent, and prostangiandin E2, a vasodilator agent, were measured
(Fig. 6). Early glycosyiation products of albumin induced a net
increase of TXB2 synthesis (102.6 8.23 pg/mi by 35 mg/mI
glycated albumin; 98.13 5.5 pg/mi by 17 mg/mi glycated
albumin, both P < 0.001 vs. basal values) that was attenuated by
aminoguanidine (50.3 1.9, 43.7 5.1, respectively; P < 0.01).
We failed to observe a stimulatory effect induced by glycated
albumin on POE2 synthesis (12.1 1.21 pg/mI by 35 mg/mI
glycated albumin; 12.4 1.4 pg/mi by 17mg/mi glycated albumin;
11.1 0.4 pg/mI in basal conditions). Normal human albumin was
ineffective on eicosanoid synthesis, while LPS increased both
TXB2 and PGE2 synthesis (TXB2, 2863 170 pg/mI; PGE2,
124.43 15.9 pg/mi; P < 0.0001 vs. basal values). Only the
stimulatory effect induced by LPS on TXB2 synthesis was blunted
by amirioguanidine (1582 38.94 pg/mI, P < 0.01 vs. values
induced by LPS).
TNF-ca synthesis
Normal albumin at concentrations of 35 mg/mI and 17 mg/mi
did not modify the basal production of TNF (1.02 0.03- and
0.94 0.01-fold increase, respectively), while at both concentra-
tions glycated albumin induced a net increase in TNF-a produc-
tion, with a 40 3.2- and 19 2.7-fold increase, respectively, in
comparison to the basal values in standard media (both P <0.001;
Fig. 7). Aminoguanidine significantly reduced the stimulatory
effect of glycated albumin (19.4 1.9-fold increase, P < 0.01).
Qualitative mRNA expression of TNF-a
Amadori adducts in glycated albumin induced the expression of
mRNA specific for TNF-n, indicating a "de novo" synthesis of this
cytokine, while normal albumin was ineffective (Fig. 8).
Discussion
Among the factors initiating the pathogenetical process leading
to diabetic nephropathy, nonenzymatic glycation of serum pro-
teins and glomerular hyperfiltration are considered the most
important contributory factors [11—19, 24]. This work is the first
report demonstrating that early glycation products of albumin in
Amadori configuration, the largest fraction of circulating glycated
proteins in vivo [10, 11, 13—17], can modulate renal hemodynamics
by modifying several endothehal cell activities, the most outstand-
ing of which is the enhancement of NOS activity. The simulta-
neous increase in gene expression of inducible NOS suggests a de
novo synthesis of the enzyme.
The phenomenon of NOS enhancement by glycated albumin
was reproducible in normal human cells, though to a lesser extent.
Our results indicate that even without a strict coincidence of the
magnitude of the effect, the enhancement of NOS activity by
Amadori adducts of glycated albumin is inducible in human cells
as well as in murine endothelial cells.
Post-Amadori glycosylation products have recently been found
to quench NO in vitro, suggesting a role for AGE in reducing
available NO molecules, thus impairing vasodilation [291. The
purification we performed by means of affinity chromatography
with phenylboronate agarose [10], according to Cohen's protocol,
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cells after incubation with glycated albumin and
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assures the recovery of a pure Amadori configurated glycated
albumin. Actually, the AGE products are eliminated by this
chromatography since they do not have the co-planar cis-hydroxyl
groups required for binding to phenylboronate.
The specificity of the stimulus of glycated albumin on NOS
activity was proven by the ineffectiveness of normal serum albu-
min and by aminoguanidine inhibition. It is well known that
aminoguanidine prevents the rearrangement of Amadori adducts
that leads to the formation of irreversible AGE products [361. The
binding of glycated albumin to its receptors on endothelial cells is
mediated by a site that binds through a lectinic bond glucose and
another one that recognizes domains in the albumin molecule
proteic portion [9]. We postulated that the modification of the
glycidic residues on glycated albumin could modify this interac-
tion.
Indeed, it is worth mentioning that aminoguanidine is a known
inhibitor of NO synthase [38].
From our data and previous reports [291, a balance between
NOS enhancement by early Amadori configurated glycosylation
adducts and NO quenching byproducts of advanced phases of
glycosylation can be envisaged.
NOS activity of endothelial cells is likely to be affected by serum
levels of various species of glycosylation products. After its
production, this short-lived gas traverses the subendothelial space
to activate smooth muscle cell guanylate cyclase, leading to
muscle relaxation and vasodilation.
A
3000
2000
P<0.001
100
P< 0.00 1
Basal Aib Glyc Glyc Aib Glyc Glyc
Aib AIb AIb Alb
mg/mi 35 35 35 17 17 17
+AMG +AMG
— -ems .. — —
U)
)1)
U)
>
U)
Cl)
U)n
0
-D0U-
Amore et at: Glycated albumin modulates NO production 33
456
Fig. 8. PCR amplification of specific mRNA encoding for TNF-o (ethidium
bromide stained gel). The lanes are: 1, native serum albumin 35 mg/mI; 2,
glycated albumin 35 mg/mI; 3, glycated albumin 35 mg/mI + AMG; 4,
normal serum albumin 17 mg/mI; 5, glycated albumin 17 mg/mI; 6, glycated
albumin 17 mg/mI + AMG; 7, LPS 10 g/ml; 8, LPS 10 jig/mI + AMG.
Amadori adducts are the predominant form of circulating
glycated proteins (accounting for 2 to 10% serum proteins) and
their concentration is highly increased in diabetes during hyper-
glycemia [11—I 3, 20, 39], while AGE levels in normal and diabetic
human sera (10 to 25 U/ml) constitute less than 0.01% of serum
proteins. Endothelial cells are therefore exposed to higher
amounts of circulating Amadori adducts than AGEs. However,
the advanced glycosylation products accumulate in subendothelial
spaces during the course of diabetes, with persisting metabolic
dysregulation. It is therefore conceivable that in the early phases
of diabetes, NOS hyperactivity enhanced by Amadori adducts
leads to vasodilation and hyperfiltration, while as AGE accumu-
lation progresses in the endothelial space, NO quenching in-
creases and vasoconstriction as well as vascular sclerosis progress.
Furthermore, NOS hyperactivity induced by Amadori adducts
in glycated albumin may be harmful because of NO-independent
effects. In fact, the intracellular amount of the natural substrate,
L-arginine, is sufficient for basal NO production, but cannot
account for highly increased requests by enhanced NOS activity,
as demonstrated during septic shock [40]. In these conditions
NOS reduces °2 to the reactive oxygen species H202 [41] or O2
[42], resulting in oxidative stress. Therefore, the stimulation of
NOS activity by glycated albumin can favor vascular damage
mediated by reactive oxygen species and peroxynitrile production
[41—431.
Besides NO synthesis, other hemodynamic factors are likely to
modulate vascular tone and progression to sclerosis, and prosta-
glandins and catecholamines are likely to be involved [44, 45].
During hyperglycemia the intracellular NADH/NAD ratio in-
creases as a consequence of hexose-monophosphate-shunt path-
way, which activates the PKC family [46]. Activation of phospho-
lipase A2 is responsible for increased prostaglandin E2 and
thromboxane A2 synthesis in hyperglycemia [471. After incubation
of endothelial cells with early adducts of glycated albumin, we
found a modification in vasoconstrictor/vasodilator products
(TXB2/PGE2) with prevalent TXB2 synthesis. We speculated that
this phenomenon could be consequent to a feedback mechanism
following increased endothelial synthesis of NO.
The outstanding pathologic features of diabetic nephropathy
are the enlargement of the mesangial area, almost exclusively
sustained by an increased production and/or reduced catabolism
of matrix components, with a simultaneously decrease of the
cellular components [48]. The coincubation of mesangial cells
with glycated albumin in Amadori configuration was shown to
induce a significant depression of mesangial proliferation [10]. We
found that a net antiproliferative effect of Amadori adducts in
glycated albumin on endothelial cells in culture, probably medi-
ated by NO, provided an antiproliferative effect. Indeed, the
coincubation with L-NAME almost completely blunted the inhib-
itory effect of glycated albumin on DNA sinthesis. However, a
direct activity of Amadori adducts has already been shown
[49 —5
All the modulations of endothelial cells metabolism we ob-
served (NO synthase stimulation, enhanced thromboxane synthe-
sis and antiproliferative effects) suggest a role for Amadori
configurated glycated albumin in several mechanisms that can be
implicated in the pathogenesis of diabetic nephropathy, ranging
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from the early to late phases. Since NO is an important mediator
involved in the regulation of proliferative activity and arachidonic
acid metabolism, we speculate that this short-lived gas plays a
driver role in the effects of early glycosylation products. However,
TNF-a is one of the most powerful stimuli to inducible NOS [27].
The production of TNF and IL-i by macrophages is enhanced
when these cells are incubated with glomerular basement mem-
brane extracts from streptozotocin-diabetic rats [30]. We detected
a significant increase in TNF-cw gene expression and release when
endothelial cells were coincubated with Amadori adducts of
glycated albumin. We could not discriminate whether or not the
synthesis of TNF-a preceeded or followed NOS stimulation;
however, the coincubation with antibody to TNF-cs almost com-
pletely reversed the stimulatory effect of glycated albumin on
endothelial cell NOS activity. This finding suggests that glycated
albumin modulates EC NOS activity by stimulating TNF-a syn-
thesis, though other, still unknown mechanisms are likely to be
involved as well.
In any case, an increase in TNF-a could play a multifaceted role
besides the stimulation of inducible NOS activity. indeed, TNF-a
enhances eicosanoid production by mesangial cells, which may be
responsible for the alteration of the glomerular microcirculation
[51]. This cytokine induces endothelial procoagulant activity and
increases endothelial permeability [31]. The relationships between
TNF-a and IL-I are strict and IL-i can stimulate collagen
synthesis by mesangial cells, which would lead to mesangial
expansion and thickening of the GBM.
Finally, our results lead us to speculate about the interpretation
of some studies on the effects of hyperglycemia on glomerular
cells activities. These studies have often been carried out by
growing cells in high concentration of glucose for at least 24 to 48
hours, conditions that can induce glycation of proteins in culture
media. Therefore, one cannot exclude the possibility that many of
the hyperglycemia-induced effects would not be consequent to
glucose per Se, but to interactions between Amadori configurated
glycated serum proteins and cell surface receptors.
Acknowledgment
This work was supported in part by a M.U.R.S.T. grant.
Reprint requests to Alessandro Amore, M.D., Divisione Nefrologia e
Dialisi, Ospedale Regina Margherita, Piazza Polonia, 94, 10126 Torino, Italy.
References
1. US RENAL DATA SYSTEM: USRDS 1992 Annual Data Report. Be-
thesda, National Institutes of Health, National Institute of Diabetes
and Digestive Kidney Diseases, 1992
2. WOLF G, SHARMA K, CHEN Y, ERICKSEN M, ZIYADEH FN: High
glucose-induced proliferation in mesangial cells is reversed by auto-
crine TGF-p. Kidney mt 42:647—656, 1992
3. LORENZI M, CAGLIERO E, TOLEDO S: Glucose toxicity for human
endothelial cells in culture: Delayed replication, disturbed cell cycle,
and accellerated death. Diabetes 34:621—627, 1985
4. HANEDA M, KIKKAWA R, HORIDE N, TOGAWA M, KOYA D, KASIWARA
N, O05HIMA A, SHIGETA Y: Glucose enhanced type IV collagen
production in cultured mesangial cells. Diabetologia 34:198—200, 1991
5. AYo SH, RADNIK GA, GARONI IA, GLASS WF, KREISBERG ii: High
glucose causes an increase in extracellular matrix proteins in cultured
mesangial cells. Am JPhysiol 260:F185—F191, 1991
6. KIIucwA R, UREMURA K, HANEDA M, ARIMURA T, EBATA K,
SHIGF.TA Y: Evidence for the existence of polyol pathway in cultured
rat mesangial cells. Diabetes 36:240—243, 1987
7. YAMAMOTO T, NAKAMURA T, NOBLE NA, RUOSLAHTI E, BORDER W:
Expression of transforming growth factor is elevated in human and
experimental diabetic nephropathy. Proc NatlAcad Sci USA 90:1814—
1818, 1993
8. MAKITA Z, RADOFF 5, RAYFIELD EJ, YANG Z, SKOLNIK E, DELANEY
V, FRIEDMAN EA, CERAMI A, VLASSARA H: Advanced glycosylation
end products in patients with diabetic nephropathy. N EngI J Med
325:836—842, 1991
9. PREDESCU D, SIMIONESCU M, SIMIONESCU N, PALADE G: Binding and
transcytosis by the microvascular endothelium of the murine myocar-
dium: Evidence that glycoalbumin behaves as a bifunctional ligand. J
Cell Biol 107:1729—1738, 1988
10. COHEN MP, ZIYADEH FN: Amadori glucose adducts modulate mes-
angial cell growth and collagen gene expression. Kidney mt 45:475—
484, 1995
11. COHEN MP: Diabetes and Protein Glycmylation: Measurement and
Biologic Relevance. New York, Springer Verlag, 1986
12. BROWNLEE M, CERAMI A, VLASSARA H: Adavenced glycosylation end
products in tissue and the biochemical basis of diabetic complications.
NEnglJMed 318:1315—1321, 1988
13. GUTHROW CE, MORRIS MA, DAY JF, THORPE SR, BAYNES J: En-
hanced non enzymatic glucosylation of serum albumin in diabetes
mellitus. Proc Nat! Acad Sci USA 76:4258—4261, 1979
14. BROWNLEE M, VLASSARA H, CERAMI A: Noncnzymatic glycosylation
and the pathogenesis of diabetic complications. Ann Intern Med
101:527—537, 1984
15. NJOROGE FG, MONNIER VM: The chemistry of the Maillard reaction
under physiological conditions: A review. Prog Clin Biol Res 304:85—
107, 1989
16. LEDL F, BECK J, SENGL M, OSIANDER H, ESTENDORFER S, SEVERIN T,
HUBER B: Chemical pathways of the Maillard reaction. Prog Clin Biol
Res 304:23—42, 1989
17. MONNIER VM, WISHWANATH V, FRANK KE, ELMETS CA, DAUCHOT P,
KOHN RR: Relation between complications of Type I diabetes mdli-
tus and collagen-linked fluorescence. NEnglJMed 314:403—408, 1986
18. MONNIER VM, KOHON RR, CERAMI A: Accelerated age-related
browning of human collagen in diabetes mellitus. Proc Nat! Acad Sci
USA 81:583—587, 1984
19. SCHNIDER SL, KOHN RR: Glucosylation of human collagen in aging
and diabetes mellitus. J Clin Invest 66:1179—1181, 1980
20. DAY JF, INGELBRETSEN WR, BAYNES JW, THORPE SR: Nonenzymatic
glycosylation of serum proteins and hemoglobin: Response to changes
in blood glucose levels in diabetic rats. Diabetes 29:524—527, 1980
21. COHEN MP, Hun E, Wu VY: Amelioration of diabetic nephropathy
by treatment with monoclonal antibodies against glycated albumin.
Kidney mt 45:1673—1679, 1994
22. COHEN MP, HUD E: Production and characterization of monoclonal
antibodies against human glycoalbumin.J ImmunolMeth 117:121—129,
1989
23. BROCIINER-MORTENSEN J: Glomerular filtration rate and extracellular
fluid volumes during normoglycemia and moderate hyperglycemia in
diabetes. Scand J Clin Lab Invest 32:311—316, 1973
24. HOSTETrER TH, TROY JL, BRENNER BM: Glomerular hemodinamics
in experimental diabetes. Kidney mt 19:410—415, 1981
25. HOSTETTER TH, RENNKE HG, BRENNER BM: The case of intrarenal
hypertension in the initiation and progression of diabetic and other
glomerulopathies. Am J Med 72:375—380, 1982
26. SABBATINI M, SANSONE G, UCCELLO F, GILIBERTI A, CONTE G,
ANDREUCCI VE: Early glycosylation products induce glomerular hy-
perflltration in normal rats. Kidney mt 42:875—881, 1992
27. MONCADA S, PALMER RMJ, HIGG5 EA: Nitric oxide: Physiology,
pathophysiology, and pharmacology. Pharmacol Rev 43:109—142, 1991
28. BANK N, AYNEDJIAN HS: Role of EDRF (nitric oxide) in diabetic
renal hyperfiltration. Kidney Int 43:1306—1312, 1993
29. BUCALA R, TRACEY 1(1, CERAMI A: Advanced glycosylation products
quench nitric oxide and mediate defective endothelium-dependent
vasodilation in experimental diabetes. J Clin Invest 87:432—438, 1991
30. HASEGAWA G, NAKANO K, SAWADA M, UNO K, SHIBAYAMA Y,
IENAGA K, KONDO M: Possible role of tumor necrosis factor and
interleukin-1 in the development of diabetic nephropathy. Kidney lot
40:1007—1012, 1991
31. BEUTLER B, CERAMI A: Cachectin: More than tumor necrosis factor.
NEnglfMed 316:379—385, 1987
32. BuSS0LIN0 F, DE RossI M, SICA A, COLOTTA F, WANG JM, B0ccHI-
Amore et a!: Glycated albumin modulates NO production 35
EYFO E, PADURA TM, BOSIA A, DEJAND F, MANTOVANI A: Murine
endothelioma cell lines transformed by polyoma middle T oncogene
as target for and producers of cytokines. J Immunol 147:2122—2129,
1993
33. WILLIAMS RL, COURTNEIDGE SA, WAGNER EF: Embiyonic lethalities
and endothelial tumors in chimeric mice expressing polyoma virus
middle T oncogene. Cell 52:121—131, 1988
34. GARLANDA C, PARRAVICINI C, Snor'io M, DE Ross! M, WAINSTOK
DE, CALAMANOVICI R, CARozzi F, BussoLiNo F, COLOi-rA F, MAN-
TOVANI A, VEcciil A: Progressive growth in immunodeficient mice
and host cell recruitment by mouse endothelial cells transformed by
polyoma middle T: Implications for the pathogenesis of opportunistic
tumors. Proc NatlAcad Sci USA 91:7291—7295, 1994
35. JAFFE EA, NACHMAN RL, BECKER CG, MINIK CR: Culture of human
endothelial cells derived from umbilical vein. J Clin Invest 52:2745—
2756, 1973
36. BROWNLEE M, VLASSARA A, KOONEY A, ULRICH P, CERAMI A:
Aminoguanidine prevents diabetes-induced arterial wall protein
cross-linking. Science 232:1629—1632, 1986
37. XIE QW, CHO Hi, CALAYCAY, MUMFOKD RA, SWIDEREK TD, LEE
TD, DING A, TRoso T, NATHAN CJ: Cloning and characterization of
inducible nitric oxide synthase from mouse macrophages. Science
256:225—228, 1992
38. GROSS SS: Nitric oxide: Pathophysiological mechanisms. Annu Revu
Physiol 57:737—769, 1995
39. COHEN MP, HOD E: Measurement of plasma glycoalbumin levels with
a monoclonal antibody based ELISA. J Immunol Meth 122:279—283,
1989
40. STUEHR Di, GRIFFITH OW: Mammalian nitric oxide synthases. Adv
Enzymol 65:287—346, 1992
41. STAMLER JS, SINGEL DJ, LoscAlzo J: Biochemistry of nitric oxide and
its redox-activated forms. Science 258:1898—1902, 1992
42. Pou S, Pou WS, BREDT DS, SNYDER SH, ROSEN GM: Generation of
superoxide by purified brain nitric oxide synthase. J Biol Chem
267:24173—24176, 1992
43. RAIJ L, BAYLIS C: Glomerular actions of nitric oxide. Kidney fnt
48:20—32, 1995
44. TESFAMARIAN B, BROWN ML, DEYKIN D, COHEN RA: Elevated
glucose promotes generation of endothelium-derived vasoconstrictor
prostanoids in rabbit aorta. J Clin invest 85:929—932, 1990
45. WEIDMANN P, BEREYITA-PICCOLO C, TROST BN: Pressor factors and
responsiveness in hypertension accompanayng diabetes mellitus. Hy-
pertension 7-11:33—42, 1985
46. DERUBERTIS FR, CRAVEN PA: Activation of protein Kinase C in
glomerular cells in diabetes. Mechanisms of potential links to the
pathogenesis of diabetic glomerulopathy. Diabetes 43:1—8, 1993
47. DE RUBERTIS FR, CRAVEN PA: Eicosanoids in the pathogenesis of the
functional and structural alterations of the kideny in diabetes. Am J
Kidney Dis 22:727—735, 1993
48. MAUER SM, STEFFES MW, ELLIS EN, SUTHERLAND DER, BROWN
DM, GOETZ FC: Structural-functional relationship in diabetic ne-
phropathy. J Clin Invest 74:1143—1155, 1984
49. COHEN MP, HOD F, Wu VY, ZIYADEH FN: Glycated albumin
modified by Amadori adducts modulates aortic endothelial cell biol-
ogy. Mol Cell Biochem 143:73—79, 1995
50. COHEN MP, SHARMA K, JIN Y, Wu VY, TOMASZEWSKI J, ZIYADEH
FN: Prevention of Diabetic nephropathy in db/db mice with glycated
albumin antagonists. A novel treatment strategy. J Clin Invest 95:
2338—2345, 1995
51. PFEILSCHIFTER J, PIGNAT W, VOSBEK K, MARKI F: Interleukin I and
tumor necrosis factor synergistically stimulate prostaglandin synthesis
and pkhospholipase A2 release from rat renal mesangial cells. Bio-
chem Biophys Res Commun 159:385—394, 1989
